These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33380149)

  • 1. [Histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Comparison of recent WHO classification published 2017 and classification of Histiocyte Society published 2016].
    Král Z; Adam Z; Ježová M; Pour L; Krejčí M
    Vnitr Lek; 2020; 66(6):19-27. PubMed ID: 33380149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of histiocytic and dendritic disorders by the 5th version of WHO Classifi cation of Hematolymphoid Tumours from 2022.
    Adam Z; Hermanová M; Horváth T; Pour L; Ševčíková S; Starý K; Dastych M; Řehák Z; Adamová Z; Král Z
    Klin Onkol; 2024; 38(3):164-177. PubMed ID: 38960672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society.
    Favara BE; Feller AC; Pauli M; Jaffe ES; Weiss LM; Arico M; Bucsky P; Egeler RM; Elinder G; Gadner H; Gresik M; Henter JI; Imashuku S; Janka-Schaub G; Jaffe R; Ladisch S; Nezelof C; Pritchard J
    Med Pediatr Oncol; 1997 Sep; 29(3):157-66. PubMed ID: 9212839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histiocytosis and Neoplasms of Macrophage-Dendritic Cell Lineages: Multimodality Imaging with Emphasis on PET/CT.
    Huynh KN; Nguyen BD
    Radiographics; 2021; 41(2):576-594. PubMed ID: 33606566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.
    Emile JF; Abla O; Fraitag S; Horne A; Haroche J; Donadieu J; Requena-Caballero L; Jordan MB; Abdel-Wahab O; Allen CE; Charlotte F; Diamond EL; Egeler RM; Fischer A; Herrera JG; Henter JI; Janku F; Merad M; Picarsic J; Rodriguez-Galindo C; Rollins BJ; Tazi A; Vassallo R; Weiss LM;
    Blood; 2016 Jun; 127(22):2672-81. PubMed ID: 26966089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing landscape of pediatric histiocytoses: Birth, life, and transdifferentiation of pediatric histiocytes.
    Auerbach A; Aguilera NS
    Semin Diagn Pathol; 2023 Nov; 40(6):420-428. PubMed ID: 37258365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia.
    Bonometti A; Ferrario G; Parafioriti A; Giardino D; Simonetti F; Ginori A; Passoni E; Berti E;
    J Cutan Pathol; 2021 May; 48(5):637-643. PubMed ID: 33188581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1 Expression and Molecular Genetic Findings in Periocular Histiocytoses and Neoplasms of Macrophage-Dendritic Cell Lineage.
    Milman T; Eiger-Moscovich M; Henry RK; Ida CM; Ruben M; Shields CL; Lally SE; Penne RB; Stefanyszyn MA; Bilyk JR; Rapuano CJ; Rabinowitz M; Eagle RC
    Am J Ophthalmol; 2022 Oct; 242():36-51. PubMed ID: 35594918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
    Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases.
    Berres ML; Allen CE; Merad M
    Adv Immunol; 2013; 120():127-61. PubMed ID: 24070383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant Histiocytosis Comprises a Phenotypic Spectrum That Parallels the Lineage Differentiation of Monocytes, Macrophages, Dendritic Cells, and Langerhans Cells.
    Ravindran A; Dasari S; Ruan GJ; Artymiuk CJ; He R; Viswanatha DS; Abeykoon JP; Zanwar S; Young JR; Goyal G; Go RS; Rech KL;
    Mod Pathol; 2023 Oct; 36(10):100268. PubMed ID: 37406859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte-rich tumours.
    Ungureanu IA; Cohen-Aubart F; Héritier S; Haroche J; Donadieu J; Emile JF
    Histopathology; 2023 Aug; 83(2):320-325. PubMed ID: 37012662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Histiocytoses: General classification and molecular criteria].
    Emile JF; Charlotte F; Chassagne-Clement C; Copin MC; Fraitag S; Mokhtari K; Moreau A
    Presse Med; 2017 Jan; 46(1):46-54. PubMed ID: 26952138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous histiocytoses in children.
    Fraitag S; Emile JF
    Histopathology; 2022 Jan; 80(1):196-215. PubMed ID: 34958507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
    Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
    Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Histiocytic diseases in childhood and adolescence].
    Vokuhl C; Oschlies I; Klapper W; Leuschner I
    Pathologe; 2015 Sep; 36(5):443-50. PubMed ID: 26292932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.
    Massoth LR; Hung YP; Ferry JA; Hasserjian RP; Nardi V; Nielsen GP; Sadigh S; Venkataraman V; Selig M; Friedmann AM; Samore W; Killian JK; Milante R; Giessinger J; Foley-Peres K; Marcus C; Severson E; Duncan D; Sivakumar S; Ross JS; Desphande V; Ramkissoon SH; Vergilio JA; Louissaint A; Zukerberg LR; Williams EA
    Oncologist; 2021 Jul; 26(7):e1263-e1272. PubMed ID: 33904632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
    Geerlinks AV; Abla O
    Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histiocytoses: clinical presentation and differential diagnosis.
    Gonzalez CL; Jaffe ES
    Oncology (Williston Park); 1990 Nov; 4(11):47-60; discussion 60, 62. PubMed ID: 2150325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cladribine is highly effective in the treatment of Langerhans cell histiocytosis and rare histiocytic disorders of the juvenile xanthogranuloma group].
    Adam Z; Szturz P; Pour L; Krejčí M; Zahradová L; Tomíška M; Král Z; Koukalová R; Rehák Z; Mayer J
    Vnitr Lek; 2012 Jun; 58(6):455-65. PubMed ID: 22913238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.